New Zealand Clinical Oncology Next Generation Sequencing Market to 2032
Overview
The New Zealand Clinical Oncology Next Generation Sequencing Market is expected to reach a 14.83 USD Million by 2032 and is projected to grow at a CAGR of 20.07% from 2025 to 2032.
Revenue, 2024 (USD Million)
4.12
Forecast, 2032 (USD Million)
14.83
CAGR, 2024 - 2032
20.07%
Report Coverage
Asia-Pacific
New Zealand Clinical Oncology Next Generation Sequencing Market 2018-2032 USD Million
New Zealand Clinical Oncology Next Generation Sequencing Market, Key Findings (2025-2032)
Market Growth and Projections:
- Market Size (2024): 4.12 USD Million
- Projected Market Size (2032): 14.83 USD Million
- CAGR (2025-2032): 20.07%
Key Findings of New Zealand Clinical Oncology Next Generation Sequencing Market
- The New Zealand Clinical Oncology Next Generation Sequencing Market was valued at 4.12 USD Million in 2024.
- The New Zealand Clinical Oncology Next Generation Sequencing Market is likely to grow at a CAGR of 20.07% during the forecast period of 2024 to 2032.
- In 2024, the Largest segment Paired End Sequencing in Sequencing Type Segment accounted for the largest share of the market with a revenue of 2.75 USD Million
- The fastest growing segment Lung Cancer in Cancer Type Segment grew Fastest with a CAGR of 23.02% during the forecast period from 2024 to 2032.
New Zealand Clinical Oncology Next Generation Sequencing Market Scope
New Zealand Clinical Oncology Next Generation Sequencing Market Segmentation & Scope
Distribution Channel
- Others
- Retail Sales
- Direct Tender
End User
- Others
- Contract Research Organizations (CROS)
- Pharmaceutical & Biotechnology Companies
- Academic & Research Institutes
- Clinical Laboratories
- Hospitals
Sequencing Type
- Single Read Sequencing
- Paired End Sequencing
Cancer Type
- Others
- Lymphoma
- Melanoma
- Prostate Cancer
- Colorectal Cancer
- Lung Cancer
- Breast Cancer
Products & Services
- Services
- Instruments
- Consumables
Technology
- Whole Genome Sequencing
- Whole Exome Sequencing
- Targeted Sequencing
New Zealand Clinical Oncology Next Generation Sequencing Market Data Coverage Insights
| Study Period | 2024-2032 |
| Base Year | 2023 |
| Unit | Revenue in USD Million |
| Market Value in 2024 | 4.12 USD Million |
| Market Value in 2032 | 14.83 USD Million |
| CAGR (2025-2032) | 20.07% |
| Historic Data | 2016-2023 |
| Market Segments Covered | Distribution Channel,End User,Sequencing Type,Cancer Type,Products & Services,Technology |
Regional Insights:
-
Leading Market (2024-2032): Asia-Pacific, leading in terms of revenue 4.12 USD Million in 2024
- Key Country: New Zealand, leading in terms of revenue with value of 4.12 USD Million in 2024.
Segments and Scope
-
New Zealand Clinical Oncology Next Generation Sequencing Market to 2032, By Distribution Channel
- Direct Tender is the largest segment in New Zealand Clinical Oncology Next Generation Sequencing Market to 2032 with a revenue of 2.49 USD Million in the year 2024.
- Retail Sales is the Fastest growing segment in New Zealand Clinical Oncology Next Generation Sequencing Market to 2032 with a Growth rate of 19.88 % in forecast period 2025-2032.
-
New Zealand Clinical Oncology Next Generation Sequencing Market to 2032, By End User
- Hospitals is the largest segment in New Zealand Clinical Oncology Next Generation Sequencing Market to 2032 with a revenue of 2.02 USD Million in the year 2024.
- Hospitals is the Fastest growing segment in New Zealand Clinical Oncology Next Generation Sequencing Market to 2032 with a Growth rate of 20.76 % in forecast period 2025-2032.
-
New Zealand Clinical Oncology Next Generation Sequencing Market to 2032, By Sequencing Type
- Paired End Sequencing is the largest segment in New Zealand Clinical Oncology Next Generation Sequencing Market to 2032 with a revenue of 2.75 USD Million in the year 2024.
- Paired End Sequencing is the Fastest growing segment in New Zealand Clinical Oncology Next Generation Sequencing Market to 2032 with a Growth rate of 20.27 % in forecast period 2025-2032.
-
New Zealand Clinical Oncology Next Generation Sequencing Market to 2032, By Cancer Type
- Lung Cancer is the largest segment in New Zealand Clinical Oncology Next Generation Sequencing Market to 2032 with a revenue of 0.97 USD Million in the year 2024.
- Lung Cancer is the Fastest growing segment in New Zealand Clinical Oncology Next Generation Sequencing Market to 2032 with a Growth rate of 23.02 % in forecast period 2025-2032.
-
New Zealand Clinical Oncology Next Generation Sequencing Market to 2032, By Products & Services
- Consumables is the largest segment in New Zealand Clinical Oncology Next Generation Sequencing Market to 2032 with a revenue of 2.27 USD Million in the year 2024.
- Consumables is the Fastest growing segment in New Zealand Clinical Oncology Next Generation Sequencing Market to 2032 with a Growth rate of 20.60 % in forecast period 2025-2032.
-
New Zealand Clinical Oncology Next Generation Sequencing Market to 2032, By Technology
- Targeted Sequencing is the largest segment in New Zealand Clinical Oncology Next Generation Sequencing Market to 2032 with a revenue of 2.31 USD Million in the year 2024.
- Targeted Sequencing is the Fastest growing segment in New Zealand Clinical Oncology Next Generation Sequencing Market to 2032 with a Growth rate of 20.41 % in forecast period 2025-2032.
New Zealand Clinical Oncology Next Generation Sequencing Market Company Share Analysis
New Zealand Clinical Oncology Next Generation Sequencing Market Geographical Sales Distribution, 2018-2032 USD Million
New Zealand Clinical Oncology Next Generation Sequencing Market Company Profiling
Industry Related Reports
Frequently Asked Questions
The New Zealand Clinical Oncology Next Generation Sequencing Market is segmented based on Segmentation Distribution Channel,End User,Sequencing Type,Cancer Type,Products & Services,Technology.
New Zealand Clinical Oncology Next Generation Sequencing Market was valued at USD 4.12(Revenue in USD Million) in 2023.
New Zealand Clinical Oncology Next Generation Sequencing Market is projected to grow at a CAGR of 20.07% during the forecast period of 2024 to 2032.
The Paired End Sequencing segment is expected to dominate the New Zealand Clinical Oncology Next Generation Sequencing Market, holding a largest market share of 2.75 USD Million in 2024
New Zealand Clinical Oncology Next Generation Sequencing Market Scope
New Zealand Clinical Oncology Next Generation Sequencing Market Segmentation & Scope
Distribution Channel
- Others
- Retail Sales
- Direct Tender
End User
- Others
- Contract Research Organizations (CROS)
- Pharmaceutical & Biotechnology Companies
- Academic & Research Institutes
- Clinical Laboratories
- Hospitals
Sequencing Type
- Single Read Sequencing
- Paired End Sequencing
Cancer Type
- Others
- Lymphoma
- Melanoma
- Prostate Cancer
- Colorectal Cancer
- Lung Cancer
- Breast Cancer
Products & Services
- Services
- Instruments
- Consumables
Technology
- Whole Genome Sequencing
- Whole Exome Sequencing
- Targeted Sequencing
Frequently Asked Questions
The New Zealand Clinical Oncology Next Generation Sequencing Market is segmented based on Segmentation Distribution Channel,End User,Sequencing Type,Cancer Type,Products & Services,Technology.
New Zealand Clinical Oncology Next Generation Sequencing Market was valued at USD 4.12(Revenue in USD Million) in 2023.
New Zealand Clinical Oncology Next Generation Sequencing Market is projected to grow at a CAGR of 20.07% during the forecast period of 2024 to 2032.
The estimated market value of the New Zealand Clinical Oncology Next Generation Sequencing Market for final year is USD 14.83 (USD Million).
New Zealand Clinical Oncology Next Generation Sequencing Market Company Profiling
Frequently Asked Questions
The New Zealand Clinical Oncology Next Generation Sequencing Market is segmented based on Segmentation Distribution Channel,End User,Sequencing Type,Cancer Type,Products & Services,Technology.
New Zealand Clinical Oncology Next Generation Sequencing Market was valued at USD 4.12(Revenue in USD Million) in 2023.
New Zealand Clinical Oncology Next Generation Sequencing Market is projected to grow at a CAGR of 20.07% during the forecast period of 2024 to 2032.
The estimated market value of the New Zealand Clinical Oncology Next Generation Sequencing Market for final year is USD 14.83 (USD Million).
CHOOSE LICENCE TYPE
- 2500.00
- 2000.00
- 1500.00
- 3200.00
- 5000.00
HAVE A QUESTION?
Get expert advice on the right strategy for your business at no cost. We also offer customized subscription plans and affordable discounts for startups and universities.